Polycystic Ovary Syndrome (PCOS) – Evidence‑Based Diagnostic and Management Guidelines

Diagnostic Criteria & Required Exclusions

Diagnose PCOS when any two of the three Rotterdam features are present—clinical/biochemical androgen excess, ovulatory dysfunction, or polycystic ovarian morphology—after excluding thyroid disease, hyperprolactinemia, and non‑classic congenital adrenal hyperplasia. 1
Exclusion testing: obtain serum TSH, prolactin, and early‑morning 17‑hydroxyprogesterone in all women to rule out thyroid disorder, hyperprolactinemia, and 21‑hydroxylase deficiency. 1, 2
If 17‑OHP > 200 ng/dL, perform an ACTH stimulation test; a stimulated level > 1,000 ng/dL confirms non‑classic congenital adrenal hyperplasia. 3
In women with amenorrhea, virilization, or atypical signs (e.g., proximal muscle weakness, frontal bossing), also exclude Cushing’s syndrome and acromegaly. 1

Clinical & Biochemical Assessment

Record hirsutism with the Ferriman‑Gallwey score (threshold ≥ 4–6 depending on ethnicity), acne, androgenic alopecia (Ludwig score), acanthosis nigricans, and skin tags. 4, 2
Define oligomenorrhea as menstrual cycles > 35 days or < 8 cycles/year; amenorrhea as ≥ 3 months of absent bleeding. 3
Assess ovulatory status via menstrual history; obtain a mid‑luteal progesterone level when cycles appear regular but anovulation is suspected. 5, 2
Measure total and free testosterone in a specialized reference laboratory (routine assays lack accuracy in the female range). 3
Measure DHEAS to evaluate adrenal androgen contribution. 3
Calculate the free androgen index (FAI) = (total testosterone ÷ SHBG) × 100. 3
Perform a pregnancy test (β‑hCG) before initiating any hormonal therapy in women with amenorrhea. 3

Imaging

Transvaginal ultrasound is the gold‑standard imaging modality in adults; polycystic ovarian morphology is diagnosed when ≥ 12 follicles (2–9 mm) per ovary or ovarian volume > 10 mL. 1
Do not rely on ovarian morphology or anti‑Müllerian hormone (AMH) levels to diagnose PCOS in adolescents, as these findings can be normal developmental variants. 2

Red‑Flag Features Requiring Urgent Evaluation

Serum testosterone > 200 ng/dL mandates immediate pelvic ultrasound and adrenal CT to exclude an androgen‑secreting tumor. 3
Rapid onset of hyperandrogenic signs (weeks–months), virilization (clitoromegaly, voice deepening, male‑pattern baldness), or a palpable abdominal/pelvic mass requires urgent imaging and endocrine referral. 3

Adolescent‑Specific Diagnostic Criteria

In adolescents, PCOS is diagnosed only when clinical or biochemical hyperandrogenism coexists with persistent oligomenorrhea > 2 years after menarche; ovarian morphology and AMH are not used. 1, 2

Metabolic & Cardiovascular Screening

Screen all women with PCOS for type 2 diabetes using a 75‑g oral glucose tolerance test (fasting and 2‑hour glucose) at diagnosis; repeat every 3–5 years or sooner if central adiposity, significant weight gain, or diabetic symptoms develop. 5, 6
HbA1c may be used when an OGTT cannot be performed, though it is less sensitive for detecting impaired glucose tolerance. 6
Obtain a fasting lipid panel at diagnosis and periodically thereafter; PCOS‑associated dyslipidemia (low HDL, elevated triglycerides, small dense LDL) occurs independent of obesity. 5, 6, 7
Measure blood pressure, calculate BMI, and record waist circumference at every visit. 5, 4
Screen overweight/obese patients for obstructive sleep apnea symptoms and confirm with polysomnography if positive. 5, 4
Assess cardiovascular risk factors: family history of premature cardiovascular disease, smoking, hypertension, dyslipidemia, and metabolic syndrome. 5, 6

Psychological & Quality‑of‑Life Screening

Screen all women and adolescents with PCOS for depression, anxiety, eating disorders, and psychosexual dysfunction through history; provide appropriate referral or treatment when identified. 5, 4, 2

First‑Line Lifestyle Intervention

Initiate a calorie‑restricted diet (500–700 kcal/day deficit) emphasizing low‑glycemic‑index foods, combined with ≥ 150 minutes/week of moderate‑to‑high‑intensity aerobic exercise, aiming for 5–10 % body‑weight loss in overweight/obese patients. 6

Pharmacologic Therapy – Menstrual Regulation & Endometrial Protection

Combined hormonal contraceptives (CHCs) are first‑line for menstrual irregularities, endometrial protection, and hyperandrogenism in women not seeking pregnancy. 6
When CHCs are contraindicated, prescribe cyclic progestins (e.g., medroxyprogesterone 10 mg for 10–14 days every 1–3 months) to induce withdrawal bleeding and protect the endometrium. 6, 2
Ensure withdrawal bleeding occurs at least every 3 months in amenorrheic patients to reduce endometrial cancer risk. 4, 2

Pharmacologic Therapy – Hyperandrogenic Symptoms

CHCs are first‑line for hirsutism and acne. 6
Add spironolactone (50–200 mg daily) as second‑line therapy for persistent hirsutism or acne, either alone or combined with CHCs. 6

Metabolic Management

Prescribe metformin (1,500–2,000 mg daily) for women with PCOS who have type 2 diabetes or impaired glucose tolerance and have failed lifestyle modification. 6
Do not use metformin as first‑line treatment for cutaneous manifestations, pregnancy complications, or obesity. 6
Do not use inositols or thiazolidinediones for PCOS treatment because of lack of benefit or safety concerns. 6
Do not use statins to treat hyperandrogenism or anovulation; reserve lipid‑lowering agents for cardiovascular risk reduction. 6

Infertility Treatment

Letrozole is first‑line ovulation induction for anovulatory infertility in PCOS. 3
Clomiphene citrate remains an alternative first‑line option. 6
Gonadotropins or laparoscopic ovarian drilling are second‑line treatments. 3
In vitro fertilization with GnRH‑antagonist protocols is reserved for refractory cases; adding metformin reduces the risk of ovarian hyperstimulation syndrome. 6
Pharmacologic ovulation induction is contraindicated in women with BMI > 35 kg/m² until weight loss is achieved. 3
Exclude other causes of infertility beyond anovulation in couples where the woman has PCOS. 5, 2

Adolescent‑Specific Treatment

CHCs are first‑line in adolescents with suspected PCOS to treat acne, hirsutism, anovulatory symptoms, or to prevent pregnancy. 6
Initiate lifestyle therapy (calorie‑restricted diet and exercise) as first‑line in overweight/obese adolescents. 6
Consider metformin when the goal is to treat impaired glucose tolerance or metabolic syndrome in adolescents. 6

Long‑Term Monitoring

Repeat OGTT every 1–2 years given the high prevalence of metabolic syndrome and type 2 diabetes in PCOS. 5
Conduct annual metabolic screening (fasting glucose, lipid panel, blood pressure). 5
Monitor for pregnancy complications (gestational diabetes, preterm birth) in women with PCOS who conceive. 5, 2
Reassess androgen levels, cutaneous signs, and menstrual regularity at 3 months after initiating therapy, then every 3–4 months for the first year. 3

Critical Pitfalls to Avoid

Do not diagnose PCOS in adolescents based solely on polycystic ovarian morphology or elevated AMH, as these can be normal developmental findings. 2
Do not attribute dyslipidemia in PCOS solely to obesity; lipid abnormalities occur independent of body weight and begin early in adulthood. 7
Do not rely on levonorgestrel‑releasing intrauterine devices to regularize menstrual cycles in PCOS, as they lack the necessary estrogen component. 7
Do not assume an ovarian source of excess testosterone when DHEAS is normal; rare adrenal adenomas can secrete pure testosterone. 3
Do not dismiss mild hyperandrogenic symptoms in adolescents; any oligomenorrhea persisting beyond 2 years post‑menarche with hyperandrogenism warrants full evaluation. 3
Do not postpone lipid screening or ignore borderline elevations in young women; lipid abnormalities begin early and persist. 7

Clinical Manifestations and Associated Risks of Polycystic Ovary Syndrome

Cutaneous Manifestations of Hyperandrogenism

The Endocrine Society recommends that clinicians document all cutaneous signs of hyperandrogenism during the physical exam. 8
Hirsutism is present in approximately 65 %–75 % of individuals with PCOS; prevalence is lower in Asian populations and severity is greater in those with abdominal obesity. 9, 10
Acne affects 14 %–25 % of women with PCOS, is most common during teenage years, and is a weaker predictor of biochemical hyperandrogenism than hirsutism. 9, 10
Androgenic alopecia (male‑pattern baldness) typically appears later than other skin signs, can be graded with the Ludwig score, and shows poor correlation with serum androgen levels. 9, 10
Acanthosis nigricans and skin tags are frequently observed, especially in obese, insulin‑resistant patients. 8, 10

Reproductive Manifestations

Approximately 50 % of women with PCOS report primary infertility and 25 % report secondary infertility. 11
Anovulatory infertility accounts for 25 %–40 % of all infertility cases, and PCOS is responsible for 70 %–90 % of ovulatory disorders. 11
Even among women with apparently regular cycles, the spontaneous ovulation rate in untreated PCOS is only about 32 % per month. 11

Metabolic and Cardiovascular Risks

Central/abdominal obesity is strongly linked to PCOS and amplifies hyperandrogenemia and metabolic complications. 8, 12, 13
Depression and anxiety are common comorbidities in PCOS and should be screened systematically. 8, 12, 13
The visible hyperandrogenic signs (hirsutism, acne, alopecia) are associated with significant psychological distress. 9, 10
Screening for obstructive sleep apnea is advised in overweight or obese patients with PCOS. 8, 12, 13
Hypertension and other cardiovascular risk factors occur more frequently in this population. 8, 13
Non‑alcoholic fatty liver disease may be present, but routine screening is not currently recommended. 8, 12

Red‑Flag Features Requiring Urgent Evaluation

Virilization (e.g., clitoromegaly, deepened voice, rapid onset of male‑pattern baldness) suggests markedly elevated androgen levels and warrants prompt imaging to exclude an androgen‑secreting tumor. 12

Age‑Specific Diagnostic Considerations

Adolescents: Diagnosis requires clinical or biochemical hyperandrogenism plus persistent oligomenorrhea lasting >2 years after menarche; ovarian morphology and anti‑Müllerian hormone are not used diagnostically because of normal developmental variation. 8, 13
Perimenopausal/Menopausal women: Diagnosis relies on a well‑documented long‑term history of oligomenorrhea and hyperandrogenism during the reproductive years, as current symptoms may be less apparent. 8, 12, 13

Pregnancy‑Related Risks

Women with PCOS have an increased risk of gestational diabetes. 8, 12, 11
The incidence of preterm birth is higher in this group. 8, 11
Pre‑eclampsia occurs more frequently among pregnant individuals with PCOS. 11
There is an elevated risk of early pregnancy loss. 11

Assessment of Ovulatory Function in Suspected PCOS

Mid‑Luteal Progesterone Measurement

Measuring serum progesterone in the mid‑luteal phase helps identify anovulation in women who report regular menstrual cycles but have suspected ovulatory dysfunction. 14

Spontaneous Ovulation Frequency

Even among women with PCOS who appear to have regular cycles, the average spontaneous ovulation rate is only about one‑third of cycles per month (≈ 32%). 14

Guideline Summary for Evaluating Hyperpigmentation and Hyperhidrosis in Women with PCOS

Cutaneous Manifestations of PCOS

Acanthosis nigricans is present in roughly 37 % of women who meet PCOS diagnostic criteria, compared with about 20 % of women who do not meet criteria. This cutaneous finding signals underlying hyperinsulinemia. 15
The lesions of acanthosis nigricans most frequently involve the axillae, neck, and other intertriginous sites. Recognition of this distribution helps differentiate it from other pigmentary disorders. 15
The Endocrine Society’s PCOS clinical guideline lists the cutaneous features that should be documented as terminal hair growth, acne, alopecia, acanthosis nigricans, and skin tags; hyperhidrosis is explicitly omitted. 16

Evaluation of Hyperhidrosis in Women with PCOS

Serum thyroid‑stimulating hormone (TSH) measurement is recommended for all women being evaluated for PCOS to exclude hyperthyroidism, a condition that can cause excessive sweating. 16
Hyperthyroidism may present with heat intolerance, profuse sweating, weight loss, and menstrual irregularities that can mimic PCOS. 17
Serum prolactin measurement is advised in every PCOS work‑up to rule out hyperprolactinemia, which can also produce oligomenorrhea and galactorrhea. 16
Early‑morning 17‑hydroxyprogesterone (17‑OHP) should be obtained in all women with suspected PCOS to exclude non‑classic congenital adrenal hyperplasia (NCCAH). 16
Primary (idiopathic) hyperhidrosis is characterized by localized excessive sweating of the palms, soles, or axillae without systemic disease. 17
Autonomic dysfunction, often associated with diabetes or metabolic syndrome (both prevalent in PCOS), can contribute to generalized hyperhidrosis. 15
Certain hormonal contraceptives and metformin, commonly used in PCOS management, may cause sweating as a medication side effect. 17

Differential Diagnosis of Hyperpigmentation Beyond Acanthosis Nigricans

Diffuse hyperpigmentation accompanied by hypotension, hyponatremia, and hyperkalemia should raise suspicion for Addison’s disease, a rare but life‑threatening adrenal insufficiency. 17
Bronze‑colored skin together with diabetes and hepatomegaly suggests hereditary hemochromatosis. 17

Key Steps in the Diagnostic Algorithm (Endocrine Society Recommendations)

Confirm PCOS by documenting at least two of the three Rotterdam criteria (clinical/biochemical androgen excess, ovulatory dysfunction, polycystic ovarian morphology). 16
Perform mandatory exclusion tests:
- TSH and free T4 to rule out thyroid disease. 16
- Serum prolactin to exclude hyperprolactinemia. 16
- Early‑morning 17‑OHP to screen for NCCAH. 16
When a velvety, symmetric hyperpigmented plaque is observed in the axillae, neck, or groin, diagnose acanthosis nigricans and proceed to metabolic screening (75‑g oral glucose tolerance test and fasting lipid panel). 15
Facial, patchy hyperpigmentation should prompt consideration of melasma or post‑inflammatory changes. 17
Generalized hyperhidrosis with heat intolerance warrants repeat thyroid testing (TSH/free T4) to evaluate for hyperthyroidism. 17
Localized hyperhidrosis confined to palms, soles, or axillae is most consistent with primary hyperhidrosis. 17
Metabolic screening for all women with PCOS includes a 75‑g oral glucose tolerance test, a fasting lipid panel, and measurement of body‑mass index and waist circumference. 15

Critical Pitfalls (Endocrine Society Guidance)

Do not attribute hyperhidrosis to PCOS; it requires independent evaluation for endocrine or neurologic causes. 16
Thyroid testing must not be omitted, as thyroid dysfunction can mimic both menstrual and sweating abnormalities seen in PCOS. 16

Red‑Flag Features Requiring Urgent Investigation

Diffuse hyperpigmentation with hypotension is a red‑flag for Addison’s disease and should trigger immediate adrenal assessment. 17

Evidence‑Based Diagnostic Framework for Polycystic Ovary Syndrome in Reproductive‑Age Women

Core Diagnostic Criteria

The diagnosis of PCOS requires the presence of any two of the three Rotterdam features—clinical or biochemical androgen excess, ovulatory dysfunction, or polycystic ovarian morphology—after excluding thyroid disease, hyperprolactinemia, and non‑classic congenital adrenal hyperplasia. 18, 19, 20

Assessment of Rotterdam Features

Clinical/Biochemical Hyperandrogenism

Hirsutism should be documented with the Ferriman‑Gallwey score, using a threshold of ≥ 4–6 points depending on the patient’s ethnic background. 18

Polycystic Ovarian Morphology

Transvaginal ultrasound (gold standard in adults) defines polycystic morphology as either ≥ 12 follicles measuring 2–9 mm per ovary or ovarian volume > 10 mL, provided no dominant follicle > 10 mm is present. 18, 21, 22
Routine universal screening with androgen assays or ultrasound is unnecessary when a patient already meets two Rotterdam criteria clinically. 18, 21, 19

Mandatory Exclusion Testing (All Women)

Serum thyroid‑stimulating hormone (TSH) should be measured to rule out thyroid disease, which can cause menstrual irregularities. 18, 21, 19, 22
Serum prolactin should be measured to exclude hyperprolactinemia, a cause of amenorrhea or hirsutism. 18, 21, 19, 22
An early‑morning (≈8 AM) serum 17‑hydroxyprogesterone (17‑OHP) level screens for non‑classic congenital adrenal hyperplasia; this condition is identified in 1.5 %–6.8 % of patients presenting with androgen excess. 18, 21, 19, 22

Age‑Specific Diagnostic Modifications

Adolescents (< 20 years, ≥ 1 year post‑menarche)

Diagnosis is permitted only when clinical or biochemical hyperandrogenism coexists with persistent oligomenorrhea lasting > 2 years after menarche; ovarian morphology and anti‑Müllerian hormone are not used because they may represent normal developmental variants. 21, 20, 22
Oligomenorrhea is common after menarche, with ≈ 85 % of cycles anovulatory in the first year and ≈ 59 % in the third year. 22
In this age group, all three Rotterdam criteria must be satisfied before confirming PCOS. 20

Perimenopausal and Menopausal Women

Diagnosis relies on a well‑documented long‑term history of oligomenorrhea and hyperandrogenism during the reproductive years; polycystic ovarian morphology on ultrasound offers supportive evidence but is less frequently observed after menopause. 20
Amenorrhea and oligomenorrhea are natural aspects of reproductive senescence, reducing the specificity of current menstrual symptoms. 18, 21, 22

Additional Diagnostic Considerations

A thorough family history should be obtained because PCOS clusters in families, affecting both female and male relatives with reproductive and metabolic abnormalities. 18, 21, 22
Clinicians must explicitly document which two (or three) Rotterdam criteria are met for each patient to ensure transparent diagnostic reasoning. 18, 21, 19, 22

Laboratory Assessment and Diagnostic Criteria for PCOS in Women with Elevated Testosterone

First‑Line Androgen Testing

Total testosterone (TT) and free testosterone (FT) measured by liquid‑chromatography‑mass spectrometry (LC‑MS) are the recommended first‑line laboratory tests for biochemical hyperandrogenism; pooled diagnostic accuracy shows TT sensitivity 0.74, specificity 0.86, AUC 0.87, and FT sensitivity 0.89, specificity 0.83, AUC 0.85【23】.

Alternative Androgen Indices

When LC‑MS is unavailable, the free androgen index (FAI = TT ÷ SHBG × 100) can be calculated; it demonstrates sensitivity 0.78, specificity 0.85, and AUC 0.87 for diagnosing PCOS【23】.

Secondary Androgen Markers

If TT or FT are not elevated, measuring androstenedione (A4) provides a sensitivity of 0.75 but lower specificity than testosterone; DHEAS has even lower diagnostic performance (sensitivity 0.60, specificity 0.79)【23】.

Integrated Diagnostic Criteria

PCOS is confirmed when elevated testosterone (measured by LC‑MS or estimated via FAI) coexists with either ovulatory dysfunction (cycles > 35 days or < 8 cycles/year) or polycystic ovarian morphology on transvaginal ultrasound (≥12 follicles 2–9 mm per ovary or ovarian volume > 10 mL), after excluding thyroid disease, hyperprolactinemia, and non‑classic congenital adrenal hyperplasia【23】.

Testing Pitfalls

Routine immunoassays on CLIA platforms lack sufficient accuracy in the female testosterone range and should not be used; only specialized reference laboratories employing mass spectrometry provide reliable results【23】.

Preconception Management of Polycystic Ovary Syndrome

Obstetric Risks Associated with PCOS

Women with polycystic ovary syndrome (PCOS) have a markedly higher incidence of gestational diabetes, preeclampsia, and pre‑term delivery, and these risks can be mitigated by metabolic assessment and optimization before conception. 24
PCOS independently raises the odds of preeclampsia by 3.5‑fold (OR 3.47; 95 % CI 1.95–6.17) after adjustment for body‑mass index. 24
The likelihood of delivering before 37 weeks is increased by 1.75‑fold (OR 1.75; 95 % CI 1.16–2.62) in pregnancies affected by PCOS. 24
Gestational diabetes occurs more often in women with PCOS, and the syndrome itself is an independent risk factor beyond the contribution of obesity. 24
Neonatal morbidity is elevated in PCOS pregnancies because of earlier gestational age at birth and maternal complications. 24

Metabolic Pathophysiology in PCOS

Insulin resistance is present in PCOS regardless of body‑mass index, affecting both lean and overweight individuals and worsening all clinical features of the syndrome. 25
Central (abdominal) obesity together with insulin resistance intensifies hyperandrogenism and aggravates metabolic complications, creating a self‑reinforcing cycle that should be interrupted before conception. 25

Preconception Metabolic Screening

A 75‑g oral glucose tolerance test (fasting and 2‑hour glucose) should be performed in all women with PCOS prior to conception to identify undiagnosed type 2 diabetes or impaired glucose tolerance. 24
The same oral glucose tolerance test should be repeated in the second trimester of pregnancy to detect gestational diabetes, given the high prevalence in this population. 24

Lifestyle Interventions

A multicomponent lifestyle program that combines a calorie‑restricted diet (≈500–700 kcal/day deficit), low‑glycemic‑index foods, ≥150 minutes/week of moderate‑to‑vigorous aerobic exercise, and behavioral counseling is central to PCOS management and should target weight reduction and healthy habits. 25
Preventing further weight gain is beneficial even when substantial weight loss is not achieved; no single dietary pattern has proven superiority over others. 25

Pharmacologic Optimization

Metformin (1,500–2,000 mg daily) is indicated for PCOS women who have type 2 diabetes or impaired glucose tolerance and have not responded adequately to lifestyle measures, to improve insulin sensitivity before pregnancy. (Guideline recommendation based on clinical evidence) 26
When metformin is used solely for PCOS without overt glucose abnormalities, it should be discontinued once pregnancy is confirmed, because it does not reduce the risk of gestational diabetes, preeclampsia, or pre‑term birth. 26

Infertility Evaluation and Ovulation Induction

In couples where the female partner has PCOS, clinicians should systematically exclude infertility causes other than anovulation (e.g., male factor, tubal obstruction) before proceeding with ovulation induction. 24
Beyond anovulation, PCOS may be associated with reduced oocyte competence and endometrial alterations that can impair implantation. 24

Overall Impact of Preconception Care

Comprehensive preconception preparation—including insulin‑resistance screening, weight optimization, menstrual regulation, hyperandrogenism control, psychological assessment, and cardiovascular risk stratification—significantly lowers maternal and neonatal morbidity in women with PCOS. [24][25]

Ovulatory Function Assessment in PCOS

Mid‑luteal Progesterone Measurement

In women with apparently regular menstrual cycles but suspected anovulation, a mid‑luteal serum progesterone drawn around cycle day 21 should be obtained.
- < 6 nmol/L (≈2 ng/mL) → defines anovulation.
- ≥ 30 nmol/L (≈9.4 ng/mL) → confirms ovulation.
- 6–30 nmol/L → requires clinical correlation.
  Evidence level not specified. 27

Ovulation Frequency in Untreated PCOS

Among women with apparently regular cycles, only ≈ 32 % have spontaneous ovulation in any given month when PCOS is untreated.
Evidence level not specified. 27